Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014 : data from the EUROlinkCAT population-based cohort study. / Damkjaer, Mads; Urhøj, Stine Kjær; Tan, Joachim; Briggs, Gillian; Loane, Maria; Given, Joanne Emma; Barrachina-Bonet, Laia; Cavero-Carbonell, Clara; Coi, Alessio; Neville, Amanda J; Heino, Anna; Kiuru-Kuhlefelt, Sonja; Jordan, Susan; Scanlon, Ieuan; Pierini, Anna; Puccini, Aurora; Garne, Ester; Morris, Joan K.
In: BMJ Open, Vol. 12, No. 4, e057400, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014
T2 - data from the EUROlinkCAT population-based cohort study
AU - Damkjaer, Mads
AU - Urhøj, Stine Kjær
AU - Tan, Joachim
AU - Briggs, Gillian
AU - Loane, Maria
AU - Given, Joanne Emma
AU - Barrachina-Bonet, Laia
AU - Cavero-Carbonell, Clara
AU - Coi, Alessio
AU - Neville, Amanda J
AU - Heino, Anna
AU - Kiuru-Kuhlefelt, Sonja
AU - Jordan, Susan
AU - Scanlon, Ieuan
AU - Pierini, Anna
AU - Puccini, Aurora
AU - Garne, Ester
AU - Morris, Joan K
N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2022
Y1 - 2022
N2 - OBJECTIVES: Advances in surgical management strategies have substantially reduced fatality from congenital heart defects (CHD). Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence. This study aims to evaluate the use of cardiovascular medication (CVM) as an indicator of disease burden in children born with CHD in the first 10 years of life.DESIGN: Population-based cohort study.SETTING: Six population-based registries from the European Surveillance of Congenital Anomalies (EUROCAT) network participated. Data from live born children with major congenital anomalies (CA) born from 2000 to 2014 were linked to prescription databases. Four groups of children were analysed: CA, CHD, severe CHD (sCHD) and ventricular septal defect (VSD) without sCHD. Live born children without CA were included as reference group.PARTICIPANTS: We obtained data on 61 038 children born with a CA, including 19 678 with CHD, 3392 with sCHD, 12 728 children with VSD without sCHD, and 1 725 496 reference children.RESULTS: Children born with sCHD were the most likely to receive a CVM prescription (42.9%, 95% CI, 26.3 to 58.5) in the first year of life compared with 13.3% (6.7 to 22.0) of children with any CHD, 5.9% (3.7 to 8.7) of children with any CA and 0.1% (0.0 to 0.1) of reference children. Medication was less likely to be prescribed after the first year of life for sCHD; 18.8% (14.8 to 23.1) for children 1-4 years and 15.8% (12.0 to 20.1) 5-9 years. Children with sCHD were most likely to receive a diuretic (36.4%, 18.6 to 54.5), an antihypertensive (6.9%, 3.7 to 11.3) or a beta-blocker (5.5%, 2.9 to9.2).CONCLUSION: Almost half of all children with sCHD were prescribed CVM in their first year of life. For all four groups of children with anomalies, the proportion of children with a CVM prescription decreased with age.
AB - OBJECTIVES: Advances in surgical management strategies have substantially reduced fatality from congenital heart defects (CHD). Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence. This study aims to evaluate the use of cardiovascular medication (CVM) as an indicator of disease burden in children born with CHD in the first 10 years of life.DESIGN: Population-based cohort study.SETTING: Six population-based registries from the European Surveillance of Congenital Anomalies (EUROCAT) network participated. Data from live born children with major congenital anomalies (CA) born from 2000 to 2014 were linked to prescription databases. Four groups of children were analysed: CA, CHD, severe CHD (sCHD) and ventricular septal defect (VSD) without sCHD. Live born children without CA were included as reference group.PARTICIPANTS: We obtained data on 61 038 children born with a CA, including 19 678 with CHD, 3392 with sCHD, 12 728 children with VSD without sCHD, and 1 725 496 reference children.RESULTS: Children born with sCHD were the most likely to receive a CVM prescription (42.9%, 95% CI, 26.3 to 58.5) in the first year of life compared with 13.3% (6.7 to 22.0) of children with any CHD, 5.9% (3.7 to 8.7) of children with any CA and 0.1% (0.0 to 0.1) of reference children. Medication was less likely to be prescribed after the first year of life for sCHD; 18.8% (14.8 to 23.1) for children 1-4 years and 15.8% (12.0 to 20.1) 5-9 years. Children with sCHD were most likely to receive a diuretic (36.4%, 18.6 to 54.5), an antihypertensive (6.9%, 3.7 to 11.3) or a beta-blocker (5.5%, 2.9 to9.2).CONCLUSION: Almost half of all children with sCHD were prescribed CVM in their first year of life. For all four groups of children with anomalies, the proportion of children with a CVM prescription decreased with age.
KW - Adolescent
KW - Cardiovascular Agents
KW - Child
KW - Cohort Studies
KW - Drug Prescriptions
KW - Female
KW - Heart Defects, Congenital/complications
KW - Heart Septal Defects, Ventricular
KW - Humans
KW - Infant
KW - Parturition
KW - Pregnancy
KW - Registries
U2 - 10.1136/bmjopen-2021-057400
DO - 10.1136/bmjopen-2021-057400
M3 - Journal article
C2 - 35450908
VL - 12
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 4
M1 - e057400
ER -
ID: 304455619